Optimal TCR-Treg therapy in T1DM involves the integration of high-affinity, multiantigen-specific T cells (targeting classical and neoantigens, such as HIP) into stable FOXP3+CD4+cells in combination with cell survival enhancers (e.g., IL-2 signaling domains). This evidence concerns the gene FOXP3 and type 1 diabetes mellitus.